Rachel McMinn

Rachel McMinn

Founder and Chief Executive OfficeratNeurogene· In proxies 2022–2025

Pay in FY2025-7% from the year before · Neurogene stock -9.9% the same year

Rachel McMinn was paid $3.2M in FY2025 (Dec), down 7%. Neurogene stock fell 9.9% that year.

Pay$100 in the stock at the end of FY21 → $21
Pay is from the Summary Compensation Table of each Neurogene proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. NeurogenePublic company · 4 yr
    • Founder and Chief Executive Officer2022 – Present · 4 yrStock in role -72%
  2. Everyone MedicinesPublic company · 5 yr
    • Director2021 – Present · 5 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?